Make poster of emergency drugs labetolol ondanseteron metaclroprmide doubtine adrelaine non adrelaine pantop Tramadol tipetodol livecretcream phenytoin dopamine avil pcm dopamine nitroglycerin vancomycin furesimide heaparin vitamin k calcium carbonate half life mechanism and half life make chart poster
Checking Date & Time
Reading File
I'll create a comprehensive emergency drugs poster. Let me first look up the key pharmacological data from the medical library, then build the poster.
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Good — I have enough data from the library combined with my pharmacology knowledge to build a comprehensive, accurate poster. Let me now create it.
Running Command
mkdir -p /home/daytona/workspace/emergency-drugs-poster && ls /home/daytona/workspace/
Writing File
~/emergency-drugs-poster/emergency_drugs_poster.html
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Emergency Drugs – Mechanism & Half-Life Reference Poster</title>
<style>
@import url('https://fonts.googleapis.com/css2?family=Roboto:wght@300;400;500;700;900&family=Oswald:wght@600;700&display=swap');
* { margin: 0; padding: 0; box-sizing: border-box; }
body {
background: #0a0a1a;
font-family: 'Roboto', sans-serif;
color: #e0e0e0;
padding: 20px;
}
.poster {
max-width: 1400px;
margin: 0 auto;
background: linear-gradient(135deg, #0d1b2a 0%, #1a0a2e 50%, #0d2a1b 100%);
border: 3px solid #ff4444;
border-radius: 16px;
padding: 30px;
box-shadow: 0 0 60px rgba(255, 68, 68, 0.4), 0 0 120px rgba(255, 68, 68, 0.1);
}
/* ── HEADER ── */
.header {
text-align: center;
margin-bottom: 28px;
position: relative;
padding-bottom: 20px;
border-bottom: 2px solid rgba(255,68,68,0.5);
}
.header::before {
content: "🚨";
font-size: 2.8rem;
display: block;
margin-bottom: 8px;
}
.header h1 {
font-family: 'Oswald', sans-serif;
font-size: 2.8rem;
font-weight: 700;
color: #ff4444;
text-transform: uppercase;
letter-spacing: 4px;
text-shadow: 0 0 20px rgba(255,68,68,0.7);
}
.header h2 {
font-size: 1.1rem;
font-weight: 300;
color: #aaa;
letter-spacing: 3px;
margin-top: 6px;
text-transform: uppercase;
}
.header .badge {
display: inline-block;
margin-top: 10px;
background: rgba(255,68,68,0.15);
border: 1px solid #ff4444;
border-radius: 20px;
padding: 4px 20px;
font-size: 0.78rem;
color: #ff9999;
letter-spacing: 2px;
}
/* ── CATEGORY LABELS ── */
.category-row {
display: flex;
gap: 10px;
margin-bottom: 18px;
flex-wrap: wrap;
justify-content: center;
}
.cat-badge {
padding: 5px 14px;
border-radius: 20px;
font-size: 0.72rem;
font-weight: 700;
letter-spacing: 1px;
text-transform: uppercase;
border: 1px solid;
}
.cat-cv { background: rgba(255,82,82,0.15); border-color: #ff5252; color: #ff8a8a; }
.cat-neuro { background: rgba(128,0,255,0.15); border-color: #9c27b0; color: #ce93d8; }
.cat-gi { background: rgba(0,188,212,0.15); border-color: #00bcd4; color: #80deea; }
.cat-ant { background: rgba(255,193,7,0.15); border-color: #ffc107; color: #ffe082; }
.cat-anal { background: rgba(76,175,80,0.15); border-color: #4caf50; color: #a5d6a7; }
.cat-anti { background: rgba(33,150,243,0.15); border-color: #2196f3; color: #90caf9; }
.cat-coag { background: rgba(255,152,0,0.15); border-color: #ff9800; color: #ffcc80; }
.cat-elec { background: rgba(233,30,99,0.15); border-color: #e91e63; color: #f48fb1; }
.cat-derm { background: rgba(0,150,136,0.15); border-color: #009688; color: #80cbc4; }
.cat-diur { background: rgba(63,81,181,0.15); border-color: #3f51b5; color: #9fa8da; }
/* ── TABLE ── */
.table-wrapper {
overflow-x: auto;
border-radius: 10px;
border: 1px solid rgba(255,255,255,0.1);
}
table {
width: 100%;
border-collapse: collapse;
font-size: 0.82rem;
min-width: 1000px;
}
thead th {
background: linear-gradient(135deg, #1a0000, #2a0000);
color: #ff4444;
font-family: 'Oswald', sans-serif;
font-size: 0.85rem;
font-weight: 600;
letter-spacing: 1.5px;
text-transform: uppercase;
padding: 14px 12px;
border-bottom: 2px solid #ff4444;
border-right: 1px solid rgba(255,255,255,0.08);
text-align: left;
white-space: nowrap;
}
thead th:last-child { border-right: none; }
tbody tr {
border-bottom: 1px solid rgba(255,255,255,0.06);
transition: background 0.2s;
}
tbody tr:hover { background: rgba(255,255,255,0.04); }
tbody td {
padding: 11px 12px;
border-right: 1px solid rgba(255,255,255,0.05);
vertical-align: top;
line-height: 1.45;
}
tbody td:last-child { border-right: none; }
/* Drug name column */
.drug-name {
font-weight: 700;
font-size: 0.88rem;
color: #fff;
white-space: nowrap;
}
.drug-generic {
font-size: 0.72rem;
color: #888;
font-style: italic;
margin-top: 2px;
}
.drug-brand {
font-size: 0.7rem;
color: #aaa;
}
/* Category pill */
.cat-pill {
display: inline-block;
padding: 2px 8px;
border-radius: 10px;
font-size: 0.68rem;
font-weight: 600;
border: 1px solid;
white-space: nowrap;
}
/* Half-life */
.hl {
font-weight: 700;
font-size: 0.92rem;
color: #ffd54f;
white-space: nowrap;
}
.hl-note {
font-size: 0.68rem;
color: #aaa;
margin-top: 2px;
}
/* Mechanism */
.moa { color: #b3e5fc; }
.moa strong { color: #4fc3f7; }
/* Dose / Route */
.dose { color: #c8e6c9; font-size: 0.78rem; }
.route {
display: inline-block;
background: rgba(255,255,255,0.08);
border-radius: 4px;
padding: 1px 5px;
font-size: 0.65rem;
margin-right: 3px;
margin-top: 2px;
color: #ccc;
}
/* Indication */
.ind { color: #e8d5f5; font-size: 0.78rem; }
/* Caution */
.caut { color: #ff8a80; font-size: 0.72rem; }
.caut::before { content: "⚠ "; }
/* Row colour accent per category */
tr.row-cv { border-left: 3px solid #ff5252; }
tr.row-neuro { border-left: 3px solid #9c27b0; }
tr.row-gi { border-left: 3px solid #00bcd4; }
tr.row-ant { border-left: 3px solid #ffc107; }
tr.row-anal { border-left: 3px solid #4caf50; }
tr.row-anti { border-left: 3px solid #2196f3; }
tr.row-coag { border-left: 3px solid #ff9800; }
tr.row-elec { border-left: 3px solid #e91e63; }
tr.row-derm { border-left: 3px solid #009688; }
tr.row-diur { border-left: 3px solid #3f51b5; }
/* ── FOOTER ── */
.footer {
margin-top: 24px;
border-top: 1px solid rgba(255,255,255,0.1);
padding-top: 16px;
display: flex;
justify-content: space-between;
align-items: center;
flex-wrap: wrap;
gap: 10px;
}
.footer-note {
font-size: 0.72rem;
color: #666;
max-width: 700px;
}
.footer-note strong { color: #ff8a80; }
.footer-date {
font-size: 0.72rem;
color: #555;
text-align: right;
}
/* Column widths */
col.c1 { width: 130px; }
col.c2 { width: 80px; }
col.c3 { width: 100px; }
col.c4 { width: 260px; }
col.c5 { width: 130px; }
col.c6 { width: 150px; }
col.c7 { width: 160px; }
</style>
</head>
<body>
<div class="poster">
<!-- HEADER -->
<div class="header">
<h1>Emergency Drugs Reference</h1>
<h2>Mechanism of Action & Half-Life Chart</h2>
<div class="badge">ICU · ER · WARD · CRITICAL CARE</div>
</div>
<!-- CATEGORY LEGEND -->
<div class="category-row">
<span class="cat-badge cat-cv">❤ Cardiovascular</span>
<span class="cat-badge cat-neuro">🧠 Neuro / Anticonvulsant</span>
<span class="cat-badge cat-gi">💊 GI / Antiemetic</span>
<span class="cat-badge cat-anal">💉 Analgesic / Opioid</span>
<span class="cat-badge cat-anti">🔵 Antibiotic</span>
<span class="cat-badge cat-coag">🟠 Anticoagulant / Reversal</span>
<span class="cat-badge cat-elec">🩸 Electrolyte</span>
<span class="cat-badge cat-diur">🟣 Diuretic</span>
<span class="cat-badge cat-ant">🟡 Antacid / GI Protective</span>
<span class="cat-badge cat-derm">🟢 Dermatology / Topical</span>
</div>
<!-- MAIN TABLE -->
<div class="table-wrapper">
<table>
<colgroup>
<col class="c1"><col class="c2"><col class="c3"><col class="c4"><col class="c5"><col class="c6"><col class="c7">
</colgroup>
<thead>
<tr>
<th># Drug Name</th>
<th>Category</th>
<th>Half-Life</th>
<th>Mechanism of Action</th>
<th>Route / Dose</th>
<th>Key Indication</th>
<th>Key Caution</th>
</tr>
</thead>
<tbody>
<!-- 1 LABETALOL -->
<tr class="row-cv">
<td>
<div class="drug-name">1. Labetalol</div>
<div class="drug-generic">labetalol HCl</div>
</td>
<td><span class="cat-pill cat-cv">CV</span></td>
<td>
<div class="hl">3 – 8 h</div>
<div class="hl-note">Onset IV: 2–5 min</div>
</td>
<td class="moa">
<strong>α₁ + β₁ + β₂ non-selective adrenergic antagonist</strong> (α:β ratio ~1:7 IV, 1:3 oral). Reduces BP by ↓ SVR without reflex tachycardia. Also has mild ISA on β₂.
</td>
<td class="dose">
<span class="route">IV</span>10–80 mg bolus;<br>
<span class="route">Infusion</span>1–2 mg/min<br>
<span class="route">PO</span>100–400 mg BD
</td>
<td class="ind">Hypertensive emergency, pre-eclampsia, aortic dissection</td>
<td class="caut">Avoid in asthma, bradycardia, AV block, decompensated HF</td>
</tr>
<!-- 2 ONDANSETRON -->
<tr class="row-gi">
<td>
<div class="drug-name">2. Ondansetron</div>
<div class="drug-generic">(Zofran)</div>
</td>
<td><span class="cat-pill cat-gi">GI</span></td>
<td>
<div class="hl">3 – 5 h</div>
<div class="hl-note">Onset IV: 30 min</div>
</td>
<td class="moa">
<strong>Selective 5-HT₃ receptor antagonist.</strong> Blocks serotonin receptors in the gut vagal afferents and chemoreceptor trigger zone (CTZ), suppressing emetic reflex.
</td>
<td class="dose">
<span class="route">IV/IM</span>4–8 mg<br>
<span class="route">PO</span>4–8 mg TDS
</td>
<td class="ind">Post-op / chemotherapy / radiation-induced nausea & vomiting</td>
<td class="caut">QT prolongation; avoid concurrent QT-prolonging drugs; serotonin syndrome risk</td>
</tr>
<!-- 3 METOCLOPRAMIDE -->
<tr class="row-gi">
<td>
<div class="drug-name">3. Metoclopramide</div>
<div class="drug-generic">(Reglan / Perinorm)</div>
</td>
<td><span class="cat-pill cat-gi">GI</span></td>
<td>
<div class="hl">4 – 6 h</div>
<div class="hl-note">Onset IV: 1–3 min</div>
</td>
<td class="moa">
<strong>Dopamine D₂ antagonist + weak 5-HT₃ antagonist + 5-HT₄ agonist.</strong> ↑ GI motility; blocks dopamine in CTZ → antiemetic. Also stimulates acetylcholine release.
</td>
<td class="dose">
<span class="route">IV/IM</span>10 mg 8-hourly<br>
<span class="route">PO</span>10 mg before meals
</td>
<td class="ind">Nausea, gastroparesis, GERD, gastric emptying</td>
<td class="caut">Extrapyramidal side effects (EPS), tardive dyskinesia; avoid in Parkinson's; reduce dose in renal impairment</td>
</tr>
<!-- 4 DOBUTAMINE -->
<tr class="row-cv">
<td>
<div class="drug-name">4. Dobutamine</div>
<div class="drug-generic">(Dobutrex)</div>
</td>
<td><span class="cat-pill cat-cv">CV</span></td>
<td>
<div class="hl">2 min</div>
<div class="hl-note">Very short; infusion only</div>
</td>
<td class="moa">
<strong>Synthetic β₁-adrenergic agonist</strong> (predominant), mild β₂ + α₁ activity. ↑ cardiac contractility (inotropy) and HR; minimal effect on SVR. ↑ CO without marked ↑ BP.
</td>
<td class="dose">
<span class="route">IV infusion</span>2–20 µg/kg/min<br>titrated to effect
</td>
<td class="ind">Acute decompensated HF, cardiogenic shock, low-output states</td>
<td class="caut">Can precipitate arrhythmias; tachycardia; caution in AF; tolerance develops within 48–72 h</td>
</tr>
<!-- 5 ADRENALINE (Epinephrine) -->
<tr class="row-cv">
<td>
<div class="drug-name">5. Adrenaline</div>
<div class="drug-generic">Epinephrine</div>
</td>
<td><span class="cat-pill cat-cv">CV</span></td>
<td>
<div class="hl">< 5 min</div>
<div class="hl-note">Plasma t½ ~2 min</div>
</td>
<td class="moa">
<strong>Non-selective α₁, α₂, β₁, β₂ adrenergic agonist (endogenous catecholamine).</strong><br>
Low dose: β-dominant → ↑HR, bronchodilation.<br>
High dose: α-dominant → ↑ SVR, vasoconstriction.<br>
↑ cAMP via adenylyl cyclase.
</td>
<td class="dose">
<span class="route">IV</span>1 mg (1:10,000) per 3–5 min CPR<br>
<span class="route">IM</span>0.3–0.5 mg (1:1,000) anaphylaxis<br>
<span class="route">Infusion</span>0.01–1 µg/kg/min
</td>
<td class="ind">Cardiac arrest (VF/PEA/asystole), anaphylaxis, severe bronchospasm</td>
<td class="caut">Hypertensive crisis, arrhythmias; avoid in cocaine toxicity; extreme tissue necrosis if extravasated</td>
</tr>
<!-- 6 NORADRENALINE (Norepinephrine) -->
<tr class="row-cv">
<td>
<div class="drug-name">6. Noradrenaline</div>
<div class="drug-generic">Norepinephrine (Levophed)</div>
</td>
<td><span class="cat-pill cat-cv">CV</span></td>
<td>
<div class="hl">1 – 2 min</div>
<div class="hl-note">Rapid MAO/COMT metabolism</div>
</td>
<td class="moa">
<strong>Potent α₁ + α₂ agonist; mild β₁ agonist; negligible β₂.</strong> Causes intense vasoconstriction → ↑ SVR → ↑ MAP. Reflex bradycardia may occur. Minimal direct chronotropy.
</td>
<td class="dose">
<span class="route">IV infusion</span>0.01–3 µg/kg/min via central line
</td>
<td class="ind">Distributive / septic shock (first-line vasopressor), neurogenic shock</td>
<td class="caut">Tissue necrosis if extravasated; ↓ renal/splanchnic blood flow; hypertension; peripheral ischaemia</td>
</tr>
<!-- 7 PANTOPRAZOLE -->
<tr class="row-ant">
<td>
<div class="drug-name">7. Pantoprazole</div>
<div class="drug-generic">(Pantop / Protonix)</div>
</td>
<td><span class="cat-pill cat-ant">PPI</span></td>
<td>
<div class="hl">1 – 2 h</div>
<div class="hl-note">Effect lasts 24 h (irreversible)</div>
</td>
<td class="moa">
<strong>Proton-pump inhibitor (PPI).</strong> Prodrug activated in acidic canaliculi → irreversibly inhibits H⁺/K⁺-ATPase (proton pump) on parietal cell luminal membrane → suppresses gastric acid secretion.
</td>
<td class="dose">
<span class="route">IV</span>40 mg OD/BD<br>
<span class="route">PO</span>20–40 mg OD
</td>
<td class="ind">GERD, peptic ulcer, stress ulcer prophylaxis, Zollinger-Ellison syndrome, upper GI bleed</td>
<td class="caut">Hypomagnesaemia (long-term); C. difficile risk; ↓ clopidogrel efficacy; B₁₂ deficiency (long-term)</td>
</tr>
<!-- 8 TRAMADOL -->
<tr class="row-anal">
<td>
<div class="drug-name">8. Tramadol</div>
<div class="drug-generic">(Ultram, Tramazac)</div>
</td>
<td><span class="cat-pill cat-anal">Analgesic</span></td>
<td>
<div class="hl">6 – 7 h</div>
<div class="hl-note">Active metabolite M1: ~9 h</div>
</td>
<td class="moa">
<strong>Dual mechanism:</strong> (1) Weak μ-opioid receptor agonist (10× weaker than morphine). (2) Inhibits reuptake of serotonin & norepinephrine in descending pain pathways. Modulates pain perception centrally.
</td>
<td class="dose">
<span class="route">IV/IM</span>50–100 mg 6-hourly<br>
<span class="route">PO</span>50–100 mg 4–6 hourly<br>Max 400 mg/day
</td>
<td class="ind">Moderate-to-severe pain, post-operative pain, neuropathic pain</td>
<td class="caut">Serotonin syndrome (with SSRIs); lowers seizure threshold; avoid in renal failure; dependence potential</td>
</tr>
<!-- 9 TAPENTADOL -->
<tr class="row-anal">
<td>
<div class="drug-name">9. Tapentadol</div>
<div class="drug-generic">(Nucynta / Tapal)</div>
</td>
<td><span class="cat-pill cat-anal">Analgesic</span></td>
<td>
<div class="hl">4 – 5 h</div>
<div class="hl-note">Immediate release form</div>
</td>
<td class="moa">
<strong>Dual mechanism (MOR-NRI):</strong> (1) μ-opioid receptor (MOR) agonist. (2) Norepinephrine reuptake inhibitor (NRI). Combines opioid + non-opioid pain modulation in a single molecule; less serotonergic activity vs tramadol.
</td>
<td class="dose">
<span class="route">PO</span>50–100 mg 4–6 hourly<br>
Max 500 mg/day (naive)<br>
Max 600 mg/day (tolerant)
</td>
<td class="ind">Moderate-to-severe acute pain, diabetic peripheral neuropathy</td>
<td class="caut">MAOIs (contraindicated); serotonin syndrome; seizure risk; dependence; avoid in severe hepatic/renal impairment</td>
</tr>
<!-- 10 LIVOCETRIZINE CREAM (Levocetirizine) -->
<tr class="row-derm">
<td>
<div class="drug-name">10. Levocetirizine</div>
<div class="drug-generic">(Livocet / Xyzal)</div>
</td>
<td><span class="cat-pill cat-derm">Antihistamine</span></td>
<td>
<div class="hl">6 – 10 h</div>
<div class="hl-note">Plasma; renal excretion</div>
</td>
<td class="moa">
<strong>Selective H₁-receptor inverse agonist</strong> (R-enantiomer of cetirizine). Stabilises H₁ receptor in inactive conformation, ↓ histamine-mediated inflammation, pruritus, bronchoconstriction, and vasodilation. Minimal CNS penetration (non-sedating).
</td>
<td class="dose">
<span class="route">PO</span>5 mg OD (evening)<br>
<span class="route">Syrup</span>2.5 mg OD (<6 yr)<br>
<span class="route">Topical cream</span>0.1% – as per indication
</td>
<td class="ind">Allergic rhinitis, chronic urticaria, atopic dermatitis, pruritus</td>
<td class="caut">Reduce dose in renal impairment (CrCl <50); somnolence at high dose; avoid alcohol</td>
</tr>
<!-- 11 PHENYTOIN -->
<tr class="row-neuro">
<td>
<div class="drug-name">11. Phenytoin</div>
<div class="drug-generic">(Dilantin / Eptoin)</div>
</td>
<td><span class="cat-pill cat-neuro">Anticonvulsant</span></td>
<td>
<div class="hl">20 – 60 h</div>
<div class="hl-note">Non-linear (Michaelis-Menten) kinetics; therapeutic range 10–20 µg/mL</div>
</td>
<td class="moa">
<strong>Voltage-gated sodium channel blocker.</strong> Binds to inactivated Na⁺ channels → prolongs inactivated state → ↓ neuronal repetitive firing. Also ↓ calcium flux across neuronal membranes.
</td>
<td class="dose">
<span class="route">IV (load)</span>15–20 mg/kg at ≤50 mg/min<br>
<span class="route">Maintenance</span>5–7 mg/kg/day<br>
<span class="route">PO</span>100 mg TDS
</td>
<td class="ind">Status epilepticus (2nd line), tonic-clonic & partial seizures, post-neurosurgery prophylaxis</td>
<td class="caut">Hypotension & arrhythmia with rapid IV; purple glove syndrome; zero-order kinetics (toxic levels with small dose changes); teratogenic (fetal hydantoin syndrome); numerous CYP450 interactions</td>
</tr>
<!-- 12 DOPAMINE -->
<tr class="row-cv">
<td>
<div class="drug-name">12. Dopamine</div>
<div class="drug-generic">(Intropin, Revimine)</div>
</td>
<td><span class="cat-pill cat-cv">Vasopressor</span></td>
<td>
<div class="hl">1 – 2 min</div>
<div class="hl-note">Rapid MAO/COMT metabolism</div>
</td>
<td class="moa">
<strong>Dose-dependent receptor activation:</strong><br>
<strong>Low (1–5 µg/kg/min):</strong> D₁/D₂ → renal & mesenteric vasodilation.<br>
<strong>Medium (5–10 µg/kg/min):</strong> β₁ → ↑ inotropy & HR.<br>
<strong>High (>10 µg/kg/min):</strong> α₁ → vasoconstriction, ↑ SVR.
</td>
<td class="dose">
<span class="route">IV infusion</span>1–20 µg/kg/min via central line
</td>
<td class="ind">Hemodynamic instability, cardiogenic shock, septic shock (2nd line), bradycardia with hypotension</td>
<td class="caut">Arrhythmias; tachycardia; tissue necrosis if extravasated; ↑ mortality in some shock states vs noradrenaline; ↓ prolactin (D₂)</td>
</tr>
<!-- 13 AVIL (Pheniramine) -->
<tr class="row-derm">
<td>
<div class="drug-name">13. Avil</div>
<div class="drug-generic">Pheniramine maleate</div>
</td>
<td><span class="cat-pill cat-derm">Antihistamine</span></td>
<td>
<div class="hl">16 – 19 h</div>
<div class="hl-note">1st-generation; renal excretion</div>
</td>
<td class="moa">
<strong>Competitive H₁ receptor antagonist</strong> (1st generation, alkylamine class). Crosses BBB → sedation, antipruritic, antiemetic effects. Also mild anticholinergic & weak local anaesthetic properties.
</td>
<td class="dose">
<span class="route">IM/IV</span>22.75–45.5 mg (1–2 mL)<br>
<span class="route">PO</span>25 mg TDS–QDS
</td>
<td class="ind">Allergic reactions, anaphylaxis (adjunct), urticaria, drug reactions, pruritus, blood transfusion reactions</td>
<td class="caut">Sedation; anticholinergic effects (urinary retention, dry mouth, glaucoma); do not use alone in anaphylaxis</td>
</tr>
<!-- 14 PARACETAMOL (PCM) -->
<tr class="row-anal">
<td>
<div class="drug-name">14. Paracetamol</div>
<div class="drug-generic">Acetaminophen (PCM / Crocin)</div>
</td>
<td><span class="cat-pill cat-anal">Analgesic/Antipyretic</span></td>
<td>
<div class="hl">1.5 – 3 h</div>
<div class="hl-note">Overdose prolongs t½ (hepatotoxicity)</div>
</td>
<td class="moa">
<strong>Central COX-3 inhibition + endocannabinoid reuptake inhibition.</strong> Inhibits prostaglandin synthesis centrally (hypothalamus) → antipyresis & analgesia. Minimal peripheral anti-inflammatory effect. Exact mechanism debated.
</td>
<td class="dose">
<span class="route">IV</span>1 g over 15 min 4–6 hourly (max 4 g/day)<br>
<span class="route">PO</span>500 mg–1 g QDS
</td>
<td class="ind">Mild-moderate pain, fever, post-operative analgesia, safe in pregnancy</td>
<td class="caut">Hepatotoxicity in overdose (via NAPQI); reduce dose in hepatic disease, malnutrition, alcohol use; antidote: N-acetylcysteine (NAC)</td>
</tr>
<!-- 15 NITROGLYCERIN -->
<tr class="row-cv">
<td>
<div class="drug-name">15. Nitroglycerin</div>
<div class="drug-generic">GTN / Glyceryl trinitrate</div>
</td>
<td><span class="cat-pill cat-cv">Vasodilator</span></td>
<td>
<div class="hl">1 – 4 min</div>
<div class="hl-note">Rapid hepatic metabolism</div>
</td>
<td class="moa">
<strong>Nitrovasodilator → releases Nitric Oxide (NO).</strong> NO activates soluble guanylyl cyclase → ↑ cGMP → smooth muscle relaxation. Predominantly venodilation (↓ preload); coronary & arterial vasodilation at higher doses (↓ afterload).
</td>
<td class="dose">
<span class="route">SL</span>0.4 mg q5 min × 3<br>
<span class="route">IV</span>5–200 µg/min infusion<br>
<span class="route">Patch</span>0.2–0.8 mg/h (12 h on/off)
</td>
<td class="ind">Acute angina, ACS, hypertensive emergency, acute pulmonary oedema, acute LV failure</td>
<td class="caut">Hypotension; headache; tolerance (nitrate-free interval required); contraindicated with PDE-5 inhibitors (sildenafil); do not use in RV infarct (preload dependent)</td>
</tr>
<!-- 16 VANCOMYCIN -->
<tr class="row-anti">
<td>
<div class="drug-name">16. Vancomycin</div>
<div class="drug-generic">(Vancocin)</div>
</td>
<td><span class="cat-pill cat-anti">Antibiotic</span></td>
<td>
<div class="hl">4 – 11 h</div>
<div class="hl-note">Normal renal function; prolonged in renal failure; TDM required</div>
</td>
<td class="moa">
<strong>Glycopeptide antibiotic.</strong> Binds to D-Ala–D-Ala terminus of peptidoglycan precursors → prevents transglycosylation & transpeptidation → inhibits bacterial cell wall synthesis. Bactericidal against Gram-positive organisms.
</td>
<td class="dose">
<span class="route">IV</span>15–20 mg/kg 8–12 hourly<br>
Infuse over ≥60 min<br>Target trough: 15–20 µg/mL (or AUC/MIC 400–600)
</td>
<td class="ind">MRSA infections, serious Gram-positive infections, C. difficile colitis (oral), endocarditis</td>
<td class="caut">Red man syndrome (slow infusion ↓ risk); nephrotoxicity; ototoxicity; dose adjust in renal impairment; TDM monitoring essential</td>
</tr>
<!-- 17 FUROSEMIDE -->
<tr class="row-diur">
<td>
<div class="drug-name">17. Furosemide</div>
<div class="drug-generic">Frusemide (Lasix)</div>
</td>
<td><span class="cat-pill cat-diur">Loop Diuretic</span></td>
<td>
<div class="hl">0.5 – 2 h</div>
<div class="hl-note">Onset IV: 2–5 min; PO: 30–60 min; prolonged in renal/hepatic failure</div>
</td>
<td class="moa">
<strong>Inhibits Na⁺-K⁺-2Cl⁻ (NKCC2) co-transporter</strong> in the thick ascending limb of Loop of Henle. ↓ reabsorption of Na⁺, K⁺, Cl⁻ → ↑ urine output. Also venodilates acutely (↓ preload before diuresis begins).
</td>
<td class="dose">
<span class="route">IV</span>20–80 mg OD/BD (titrate)<br>
<span class="route">PO</span>20–120 mg OD/BD<br>
High-dose infusion: 5–40 mg/h
</td>
<td class="ind">Acute pulmonary oedema, heart failure, hypertension, hypercalcaemia, hyperkalaemia, oliguric renal failure</td>
<td class="caut">Hypokalaemia; hyponatraemia; hypovolaemia; hypocalcaemia; ototoxicity (rapid high-dose IV); gout; monitor electrolytes</td>
</tr>
<!-- 18 HEPARIN -->
<tr class="row-coag">
<td>
<div class="drug-name">18. Heparin</div>
<div class="drug-generic">Unfractionated Heparin (UFH)</div>
</td>
<td><span class="cat-pill cat-coag">Anticoagulant</span></td>
<td>
<div class="hl">1 – 2 h</div>
<div class="hl-note">Dose-dependent; prolonged in PE/massive thrombus; monitor aPTT</div>
</td>
<td class="moa">
<strong>Activates antithrombin III (AT-III)</strong> by conformational change → AT-III irreversibly inhibits thrombin (IIa), Xa, IXa, XIa, XIIa. ↓ clot formation. Does NOT lyse existing clots. Reversed by protamine sulphate.
</td>
<td class="dose">
<span class="route">IV bolus</span>80 units/kg<br>
<span class="route">Infusion</span>18 units/kg/h (titrate to aPTT 60–100 s)<br>
<span class="route">SC prophylaxis</span>5,000 units BD/TDS
</td>
<td class="ind">DVT/PE treatment & prophylaxis, ACS, atrial fibrillation, CPB, haemodialysis</td>
<td class="caut">HIT (heparin-induced thrombocytopaenia) – check platelets; bleeding risk; osteoporosis (long-term); antidote: protamine (1 mg per 100 units heparin)</td>
</tr>
<!-- 19 VITAMIN K -->
<tr class="row-coag">
<td>
<div class="drug-name">19. Vitamin K</div>
<div class="drug-generic">Phytomenadione (Konakion)</div>
</td>
<td><span class="cat-pill cat-coag">Coag Reversal</span></td>
<td>
<div class="hl">17 h</div>
<div class="hl-note">Warfarin reversal: 6–12 h for INR effect</div>
</td>
<td class="moa">
<strong>Cofactor for γ-carboxylation of Gla-proteins.</strong> Activated by vitamin K epoxide reductase → carboxylates clotting factors II, VII, IX, X (and proteins C & S). Reverses warfarin/coumarin anticoagulation. Essential for haemostasis.
</td>
<td class="dose">
<span class="route">IV (slow)</span>2–10 mg over 30 min<br>
<span class="route">IM/SC</span>10 mg<br>
<span class="route">Neonates</span>1 mg IM at birth (HDN prophylaxis)
</td>
<td class="ind">Warfarin reversal, haemorrhagic disease of newborn (HDN), liver disease coagulopathy, vitamin K deficiency</td>
<td class="caut">Anaphylaxis with rapid IV (give slowly); will not correct factor replacement in emergencies (FFP faster); takes hours for full effect</td>
</tr>
<!-- 20 CALCIUM CARBONATE -->
<tr class="row-elec">
<td>
<div class="drug-name">20. Calcium Carbonate</div>
<div class="drug-generic">(Caltrate, Shelcal)</div>
</td>
<td><span class="cat-pill cat-elec">Electrolyte</span></td>
<td>
<div class="hl">Variable</div>
<div class="hl-note">Calcium t½: ~1 h IV; depot effect PO; skeletal storage</div>
</td>
<td class="moa">
<strong>Calcium supplementation + phosphate binder (in CKD).</strong> Replenishes Ca²⁺ for membrane stabilisation, myocardial contractility, neuromuscular function, coagulation (factor IV). In CKD: binds dietary phosphate in gut → ↓ hyperphosphataemia. IV calcium gluconate stabilises cardiac membranes in hyperkalaemia.
</td>
<td class="dose">
<span class="route">PO</span>500 mg–1.5 g TDS with meals<br>
<span class="route">Calcium gluconate IV</span>10 mL of 10% slow IV (cardiac stabilisation in hyperkalaemia)<br>
<span class="route">Calcium chloride IV</span>5–10 mL of 10%
</td>
<td class="ind">Hypocalcaemia, osteoporosis, CKD-mineral bone disorder (MBD), hyperkalaemia (cardiac membrane stabilisation), antacid</td>
<td class="caut">Hypercalcaemia; constipation; interactions with iron, tetracyclines; digoxin toxicity ↑ with Ca²⁺; nephrolithiasis with excess</td>
</tr>
</tbody>
</table>
</div>
<!-- QUICK HALF-LIFE SUMMARY BAR -->
<div style="margin-top: 22px;">
<div style="font-family: 'Oswald', sans-serif; font-size: 0.9rem; color: #ff4444; letter-spacing: 2px; text-transform: uppercase; margin-bottom: 10px;">⏱ Quick Half-Life Reference</div>
<div style="display: flex; flex-wrap: wrap; gap: 8px;">
<!-- Ultra-short -->
<div style="background: rgba(255,82,82,0.12); border: 1px solid rgba(255,82,82,0.3); border-radius: 8px; padding: 8px 14px; min-width: 160px;">
<div style="font-size: 0.65rem; color: #ff8a8a; text-transform: uppercase; letter-spacing: 1px; margin-bottom: 5px;">Ultra-Short (< 5 min)</div>
<div style="font-size: 0.75rem; color: #eee; line-height: 1.7;">
Adrenaline — <b><2 min</b><br>
Noradrenaline — <b>1–2 min</b><br>
Dopamine — <b>1–2 min</b><br>
Dobutamine — <b>~2 min</b><br>
Nitroglycerin — <b>1–4 min</b>
</div>
</div>
<!-- Short -->
<div style="background: rgba(255,193,7,0.1); border: 1px solid rgba(255,193,7,0.3); border-radius: 8px; padding: 8px 14px; min-width: 160px;">
<div style="font-size: 0.65rem; color: #ffe082; text-transform: uppercase; letter-spacing: 1px; margin-bottom: 5px;">Short (30 min – 3 h)</div>
<div style="font-size: 0.75rem; color: #eee; line-height: 1.7;">
Furosemide — <b>0.5–2 h</b><br>
Paracetamol — <b>1.5–3 h</b><br>
Nitroglycerin — <b>1–4 min</b><br>
Pantoprazole — <b>1–2 h</b><br>
Heparin — <b>1–2 h</b>
</div>
</div>
<!-- Moderate -->
<div style="background: rgba(76,175,80,0.1); border: 1px solid rgba(76,175,80,0.3); border-radius: 8px; padding: 8px 14px; min-width: 160px;">
<div style="font-size: 0.65rem; color: #a5d6a7; text-transform: uppercase; letter-spacing: 1px; margin-bottom: 5px;">Moderate (3 – 10 h)</div>
<div style="font-size: 0.75rem; color: #eee; line-height: 1.7;">
Labetalol — <b>3–8 h</b><br>
Ondansetron — <b>3–5 h</b><br>
Metoclopramide — <b>4–6 h</b><br>
Tramadol — <b>6–7 h</b><br>
Tapentadol — <b>4–5 h</b><br>
Levocetirizine — <b>6–10 h</b><br>
Vancomycin — <b>4–11 h</b>
</div>
</div>
<!-- Long -->
<div style="background: rgba(33,150,243,0.1); border: 1px solid rgba(33,150,243,0.3); border-radius: 8px; padding: 8px 14px; min-width: 160px;">
<div style="font-size: 0.65rem; color: #90caf9; text-transform: uppercase; letter-spacing: 1px; margin-bottom: 5px;">Long (>10 h)</div>
<div style="font-size: 0.75rem; color: #eee; line-height: 1.7;">
Avil (Pheniramine) — <b>16–19 h</b><br>
Vitamin K — <b>~17 h</b><br>
Phenytoin — <b>20–60 h</b><br>
Calcium Carbonate — <b>variable</b>
</div>
</div>
</div>
</div>
<!-- FOOTER -->
<div class="footer">
<div class="footer-note">
<strong>⚠ Clinical Disclaimer:</strong> This chart is a quick-reference educational tool only. Always verify doses, contraindications, and drug interactions with current formularies, institutional protocols, and clinical judgment. Half-lives may vary with renal/hepatic impairment, age, drug interactions, and pathological states.
</div>
<div class="footer-date">
Generated: April 2026<br>
Sources: Katzung Pharmacology 16e · Washington Manual · Miller's Anesthesia 10e · Lippincott Pharmacology
</div>
</div>
</div>
</body>
</html>
Now let me convert this to a PDF poster:
Running Command
which wkhtmltopdf chromium-browser google-chrome 2>/dev/null; python3 -c "import weasyprint; print('weasyprint ok')" 2>/dev/null || echo "checking other options"
Running Command
python3 -c "from weasyprint import HTML; print('weasyprint available')" 2>&1; python3 -c "import pdfkit; print('pdfkit available')" 2>&1
Running Command
which libreoffice soffice pandoc 2>/dev/null; python3 -c "from reportlab.lib.pagesizes import A1; print('reportlab ok')" 2>&1
Running Command
cd /home/daytona/workspace/emergency-drugs-poster && libreoffice --headless --convert-to pdf emergency_drugs_poster.html --outdir . 2>&1
Running Command
cp /home/daytona/workspace/emergency-drugs-poster/emergency_drugs_poster.html /tmp/ep.html && libreoffice --headless --convert-to pdf /tmp/ep.html --outdir /tmp/ 2>&1 && cp /tmp/ep.pdf /home/daytona/workspace/emergency-drugs-poster/emergency_drugs_poster.pdf && echo "PDF created" && ls -lh /home/daytona/workspace/emergency-drugs-poster/
Both files are ready. Let me mark the task complete.Your emergency drugs poster is ready! Here are your download links:
📥 Download Files
| Format | Link |
|---|---|
| HTML (interactive, best rendering) | emergency drugs poster HTML File · HTML |
| PDF (print-ready) | emergency drugs poster PDF Document · PDF |
What's included in the poster
The poster is a dark-themed, color-coded reference chart covering all 20 drugs you listed (with corrected spellings):
| # | Drug | Category |
|---|---|---|
| 1 | Labetalol | Cardiovascular (α+β blocker) |
| 2 | Ondansetron | GI / Antiemetic |
| 3 | Metoclopramide | GI / Antiemetic |
| 4 | Dobutamine | Cardiovascular (inotrope) |
| 5 | Adrenaline (Epinephrine) | Cardiovascular / Emergency |
| 6 | Noradrenaline (Norepinephrine) | Cardiovascular / Vasopressor |
| 7 | Pantoprazole | PPI / GI Protective |
| 8 | Tramadol | Analgesic |
| 9 | Tapentadol | Analgesic |
| 10 | Levocetirizine (Livocet cream) | Antihistamine / Dermatology |
| 11 | Phenytoin | Anticonvulsant |
| 12 | Dopamine | Vasopressor / Inotrope |
| 13 | Avil (Pheniramine) | Antihistamine |
| 14 | Paracetamol (PCM) | Analgesic / Antipyretic |
| 15 | Nitroglycerin (GTN) | Vasodilator |
| 16 | Vancomycin | Antibiotic |
| 17 | Furosemide | Loop Diuretic |
| 18 | Heparin | Anticoagulant |
| 19 | Vitamin K | Coagulation Reversal |
| 20 | Calcium Carbonate | Electrolyte |
Each drug entry contains:
- Mechanism of Action (detailed, receptor-level)
- Half-Life (with onset notes)
- Route & Emergency Dose
- Key Indications
- Key Cautions / Contraindications
Plus a color-coded Quick Half-Life Summary bar grouping drugs into Ultra-Short / Short / Moderate / Long categories.
Note: Drug names were interpreted and corrected from your list (e.g. doubtine → Dobutamine, adrelaine → Adrenaline, non adrelaine → Noradrenaline, tipetodol → Tapentadol, livecretcream → Levocetirizine, furesimide → Furosemide, heaparin → Heparin). Let me know if any drug needs to be changed.
This is a shared conversation. Sign in to Orris to start your own chat.